MOZ/ENL complex is a recruiting factor of leukemic AF10 fusion proteins

Komata, Yosuke; Kanai, Akinori; Maeda, Takahiro; Inaba, Toshiya; Yokoyama, Akihiko

doi:10.1038/s41467-023-37712-5

Download PDF

Article
Open access
Published: 08 April 2023

MOZ/ENL complex is a recruiting factor of leukemic AF10 fusion proteins

Nature Communications volume 14, Article number: 1979 (2023) Cite this article

2185 Accesses
2 Citations
13 Altmetric
Metrics details

Subjects

Abstract

Changes in the transcriptional machinery cause aberrant self-renewal of non-stem hematopoietic progenitors. AF10 fusions, such as CALM-AF10, are generated via chromosomal translocations, causing malignant leukemia. In this study, we demonstrate that AF10 fusion proteins cause aberrant self-renewal via ENL, which binds to MOZ/MORF lysine acetyltransferases (KATs). The interaction of ENL with MOZ, via its YEATS domain, is critical for CALM-AF10-mediated leukemic transformation. The MOZ/ENL complex recruits DOT1L/AF10 fusion complexes and maintains their chromatin retention via KAT activity. Therefore, inhibitors of MOZ/MORF KATs directly suppress the functions of AF10 fusion proteins, thereby exhibiting strong antitumor effects on AF10 translocation-induced leukemia. Combinatorial inhibition of MOZ/MORF and DOT1L cooperatively induces differentiation of CALM-AF10-leukemia cells. These results reveal roles for the MOZ/ENL complex as an essential recruiting factor of the AF10 fusion/DOT1L complex, providing a rationale for using MOZ/MORF KAT inhibitors in AF10 translocation-induced leukemia.

TAF1 plays a critical role in AML1-ETO driven leukemogenesis

Article Open access 29 October 2019

ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism

Article Open access 16 February 2021

The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia

Article 26 November 2022

Introduction

Acute leukemia is a major cause of death in children with cancers. Our understanding of the underlying molecular mechanisms of leukemia and the availability of effective treatment methods have not met the current medical needs. Alterations in the genes encoding epigenetic regulators, such as lysine methyltransferases (KMTs), including MLL (also known as KMT2A), and lysine acetyltransferases (KATs), including MOZ (also known as KAT6A and MYST3) and MORF (also known as KAT6B, MYST4, and QKF), cause leukemia by conferring stem cell-like unlimited self-renewal properties to non-stem hematopoietic progenitors^1,2.

AF10 (also known as MLLT10) and ENL family proteins, including ENL (also known as MLLT1) and AF9 (also known as MLLT3), are major fusion partners of MLL³. AF10 and ENL family proteins form a complex with DOT1L KMT, which methylates histone H3 lysine 79^4,5. The DOT1L complex co-localizes with the MLL KMT complex and other ENL-containing transcriptional regulators, including the AF4 family/ENL family/P-TEFb (AEP) and MOZ/MORF KAT complexes, at the promoter-proximal transcribed regions of transcriptionally active genes^6,7,8. ENL was not found as a complex component of MOZ/MORF in the early biochemical purifications of stably assembled complexes⁹, suggesting that ENL is a transient interactor that binds to MOZ/MORF in a context-dependent manner⁷. MOZ/MORF and HBO1 (also known as KAT7 and MYST2) constitute a subgroup of functionally similar KATs termed the MYST family. HBO1 physically associates with the MLL complex and co-localizes with those ENL-containing protein complexes^10,11. These epigenetic and transcriptional regulators comprise a transcriptional activation system (hereafter referred to as the MLL/MOZ/AEP-mediated transcriptional activation system), which activates a range of CpG-rich promotors through multiple cell divisions¹². During embryonic development, CpG-rich promoters are regulated by polycomb group (PcG) and trithorax group (TrxG) complexes^13,14. This MLL/MOZ/AEP-mediated transcriptional activation system plays a major role in the maintenance of gene expression during embryonic development and in the self-renewal of hematopoietic stem cells during normal hematopoietic development^15,16,17,18.

Gene rearrangements of AF10 generate diverse AF10 fusion proteins with many partners besides MLL, including CALM (also known as PICALM), DDX3X, NUP98, and XPO1 (also known as CRM1), causing multiple lineages of malignant leukemia, including acute myeloid (AML), B-cell acute lymphoblastic (B-ALL), and T-cell acute lymphoblastic leukemia (T-ALL)^{19,20,21,22,23}. Because the AF10/DOT1L complex co-localizes with MLL and MOZ at CpG-rich promoters and shares ENL as a component with MOZ and AEP complexes⁷, we hypothesized that AF10 fusions might promote their oncogenic activity by overactivating the MLL/MOZ/AEP-mediated transcriptional activation system, similar to the functions of MLL and MOZ fusions.

In this work, we investigated the structural and functional requirements of AF10 fusions for oncogenic transformation in murine disease models. This is the first study to reveal the ENL/MOZ complex as an essential co-factor for AF10 fusion protein complex recruitment to target promoters. We suggest that the ENL/MOZ complex can serve as a potential therapeutic target in AF10 translocation-induced leukemia.

Results

AF10 fusions transform hematopoietic progenitors via ENL

Aberrant self-renewal induced by overactivation of the MLL/MOZ/AEP-mediated transcriptional activation system can be evaluated by an ex vivo myeloid progenitor transformation assay⁷. In this assay, oncogene-transduced c-Kit-positive hematopoietic progenitor cells (HPCs) that are harvested from the bone marrow (BM) of healthy mice are cultured in semi-solid media in the presence of myeloid cytokines²⁴. Cells transduced with a functional oncogene typically exhibit upregulated Hoxa9 expression in the first-round colonies as well as vigorous colony-forming activity in the third and fourth rounds of replating (Fig. 1a and Supplementary Fig. 1). The structural requirements of MLL-AF10 were the minimum targeting module (MTM: PWWP domain of LEDGF and CXXC domain of MLL) that binds to the target chromatin²⁵, THD2 domain of MLL that recruits an HBO1 complex¹⁰, and OM-LZ domain of AF10 that binds to DOT1L HMT^5,8. An artificial fusion of MTM and the THD2 domain (hereafter referred to as MTMT) tethered to the full-length DOT1L, instead of the OM-LZ domain, transformed HPCs (see MTMT-DOT1L in Fig. 1a). The MTMT-DOT1L constructs with mutations deficient in KMT activity (i.e., MTMT-DOT1L dKMT) or the ability to bind ENL (i.e., MTMT-DOT1L dMISD) failed to transform, thereby indicating that both KMT activity and ENL association are necessary for MLL-AF10-mediated leukemic transformation. Replacement of the OM-LZ domain by the full-length ENL also caused a full transformation, highlighting the importance of ENL association (see MTMT-ENL in Fig. 1a). A minimum fusion protein (i.e., MTM-AHD) comprising MTM and the ANC1 homology domain (AHD) of ENL, which binds to the AEP components, transformed HPCs²⁵, indicating that the tethering of AEP to the MLL target chromatin is the central mechanism of overactivation of the MLL/MOZ/AEP-mediated transcriptional activation system¹². These results suggested that MLL-AF10 provides ENL to the MLL target chromatin to recruit AEP^8,10.

The CALM-AF10 fusion transforms immature HPCs in mice²⁶ and causes T-ALL, B-ALL, and AML in humans²⁷. The minimum structural requirements of CALM-AF10 are the nuclear export signal (NES) of CALM and the OM-LZ domain of AF10 (see NES-AF10´ in Fig. 1a)^26,28,29. Artificial gene constructs of ENL fused with CALM or NES (see CALM-ENL or NES-ENL in Fig. 1a) transformed HPCs (although the NES-DOT1L fusion did not), indicating that association with ENL is essential in CALM-AF10-mediated leukemic transformation. As wild-type ENL did not transform HPCs, NES appeared to confer the gain-of-function to ENL to aberrantly activate Hoxa9. Immunoprecipitation (IP) followed by western blotting (WB) in DOT1L-deficient cells demonstrated that the NES-AF10´ fusion interacted with ENL in a DOT1L-dependent manner (Fig. 1b). Transplantation of NES-ENL-transduced HPCs resulted in leukemia in vivo, which was recapitulated in the secondary recipients (Fig. 1c). These results indicated that CALM-AF10 transformed HPCs via ENL.

Next, we assessed various other AF10 fusions including DDX3X-AF10 and NUP98-AF10^23,30, using the ex vivo myeloid progenitor transformation assays. Both DDX3X-AF10 and NUP98-AF10 transformed HPCs via the OM-LZ domain, which was interchangeable with ENL (Fig. 1a and Supplementary Fig. 1). RNA-sequencing (RNA-seq) analysis of three independently established immortalized cells (ICs) with each AF10 fusion type revealed that they expressed a similar gene set including HoxA genes, which is different from that in the originating HPCs (i.e., c-Kit+ BM; Fig. 1d and Supplementary Fig. 2a–c). Other differentially expressed genes in c-Kit + -BM and AF10 fusion-ICs are the genes implicated in the lysosome, hemopoiesis, and lipid biosynthesis (Supplementary Fig. 2d, e). CALM-AF10- and NES-ENL-ICs tended to have near-identical expression profiles, which was also similar to those of MLL-AF10-ICs, while NUP98-AF10´- and DDX3X-AF10´-ICs expressed slightly different gene sets, which included the genes implicated in MAPK cascades, suggesting that the activation status of proliferative signaling pathways may be different among the AF10 fusion subtypes (Supplementary Fig. 2c, f, g). These results suggest that AF10 fusions transform hematopoietic progenitors by activating similar gene sets including HoxA genes via ENL.

MOZ recruits ENL and DOT1L to HOXA gene promoters

We examined the genomic localization of ENL and other functionally related components using chromatin immunoprecipitation (ChIP) coupled with deep sequencing (ChIP-seq)^7,10. In HEK293T cells, ENL was co-localized at promoter-proximal regions with the DOT1L, MOZ, and AEP complexes (e.g., AF4) and HBO1¹⁰ (Fig. 2a and Supplementary Fig. 3a). ENL-target promoters were enriched with RNA Polymerase II (RNAP2) with a non-phosphorylated CTD heptapeptide motif (RNAP2 non-P) bound by MOZ⁷. The ChIP signal intensity of ENL was positively correlated with that of the MOZ, DOT1L, AEP, and HBO1 complexes, sharing common target genes (Supplementary Fig. 3b, c). These results suggest that ENL functionally collaborates with MOZ, DOT1L, AEP, and HBO1 at promoter-proximal regions.

Next, we generated MOZ- and DOT1L-deficient HEK293T clones (two biological replicates each; Fig. 2b) and analyzed them using WB, reverse transcription (RT) coupled with quantitative polymerase chain reaction (qPCR), and ChIP-qPCR analyses. The MOZ-deficient clones exhibited reduced HOXA5 and HOXA9 expression levels (Fig. 2c). In addition, MOZ is necessary for the presence of ENL and DOT1L at the HOXA loci, but not at the MYC locus, as shown by a genome-wide analysis of the localizations of ENL and DOT1L in MOZ-deficient cells (Fig. 2d). Reduced ENL ChIP signal was uniquely seen at a subset of ENL target genes including HOXA genes (Fig. 2e and Supplementary Fig. 3d). Furthermore, ChIP signals of DOT1L were severely reduced at the HOXA loci as well by MOZ knockout (Fig. 2f and Supplementary Fig. 3d). These results suggest that HOXA genes, but not all ENL-target genes, are regulated dependently on MOZ. Moreover, ChIP-qPCR analysis confirmed that the chromatin occupancy of DOT1L and ENL was profoundly reduced at the HOXA loci in MOZ-deficient cells (Fig. 2g), indicating that MOZ is required for ENL and DOT1L recruitment at the HOXA gene promoters. Additionally, the DOT1L-deficient clones demonstrated reduced levels of HOXA5 and HOXA9 expression (Fig. 2c) and the localization of ENL at the HOXA loci (Fig. 2g), suggesting that the continued presence of the DOT1L/ENL complex is required for sustained HOXA gene expression. The chromatin occupancy of MOZ was moderately reduced (30–50%) in DOT1L-deficient cells, suggesting a positive feedback loop. These results indicated that the MOZ/ENL complex recruits DOT1L to HOXA gene promoters.

NES-ENL fusion binds to the target gene promoters via the YEATS and AHD domains of ENL

We evaluated the structural requirements of NES-ENL-dependent leukemic transformation by the ex vivo myeloid progenitor transformation assay (Fig. 3a and Supplementary Fig. 4a). Deleting the AHD domain resulted in complete loss of transformation (see NES-dAHD in Fig. 3a), indicating that the interaction with AHD binders (e.g., AF4 or DOT1L) is required for transformation. Unlike the MLL-ENL fusion (see MTM-AHD in Fig. 1a), deletion of the non-AHD portion of ENL resulted in a loss of transformation (see NES-AHD in Fig. 3a). Moreover, a loss-of-function mutation of the YEATS domain^7,31,32 (i.e., Y78A) resulted in a loss of transformation, suggesting that the YEATS-mediated interaction with acetylated histones or MOZ/MORF KATs is required for CALM-AF10-mediated leukemia. An artificial construct of AF9 fused with the NES (i.e., NES-AF9) transformed HPCs. These results suggest that ENL and AF9 are commonly associated with transformation. NES of CALM has been reported to interact with XPO1, a nuclear export receptor also known as CRM1³³. An artificial fusion of XPOI and ENL activated Hoxa9 and immortalized HPCs, suggesting that NES-ENL activates Hoxa9 expression via interaction with XPO1. In addition, stable expression of NES-ENL in HEK293T cells resulted in elevated expression of HOXA5 and HOXA9 (Fig. 3b, c). This indicates that NES-ENL is a gain-of-function mutant of ENL that can activate HOX genes in both HPCs and HEK293T cells via a common mechanism.

**Fig. 3: Structural requirements of NES-ENL in overactivation of *HOX* genes.**

Next, we examined ENL-mediated protein interactions in the chromatin fraction using the fanChIP method, which captures protein-protein interaction in the chromatin fraction³⁴. The Y78A mutation abrogated the association of NES-ENL with MOZ, whereas the AHD deletion resulted in a loss of interaction with DOT1L and Cyclin T1 (Fig. 3d). MOZ-ENL interaction was detected in DOT1L-deficient cells (Supplementary Fig. 4b), suggesting that MOZ/ENL complex formation occurs independently of DOT1L/ENL complex formation. Because the defective mutations in the YEATS and AHD domains showed no transformation activity in HPCs (Fig. 3a), both of the associations with MOZ and DOT1L seem essential for NES-ENL-mediated transformation. In addition, ChIP-qPCR analysis of HEK293T cell lines expressing various ENL constructs showed that wild-type ENL was associated with the promoter regions of HOXA5 and HOXA9, similar to CALM-AF10 (Fig. 3e), indicating that ENL can target these promoters. Furthermore, NES-ENL exhibited a similar targeting ability, whereas defective mutations in the YEATS and AHD domains completely abrogated it. Thus, the stable association of ENL with target chromatin requires YEATS- and AHD-mediated interactions. Taken together, chromatin targeting by CALM-AF10 is mediated by the MOZ/ENL complex, whose complex formation depends on the YEATS domain.

ENL, DOT1L, and MYST family KATs are required for CALM-AF10 leukemia cells

To examine whether ENL, DOT1L, and MYST family KATs are required for CALM-AF10 leukemia cell proliferation, we performed CRISPR/Cas9-mediated competition assays on murine and human leukemia cells. Like MLL-ENL-ICs, the proliferation of CALM-AF10-ICs depended on both Enl and Dot1l (Fig. 4a). Moz knockout quickly eliminated CALM-AF10-ICs, while it also attenuated the proliferation of MLL-ENL-ICs. Morf knockout did not dramatically affect the proliferation of CALM-AF10-ICs or MLL-ENL-ICs, suggesting that MOZ is the predominant ortholog in these cell types. These tendencies were consistently observed using multiple different sgRNAs (Supplementary Fig. 5). Moreover, Brpf1, a common component of MOZ/MORF complexes, was also required for both cell types. HBO1 is required for both CALM-AF10 and MLL-ENL, as it is generally required for the survival of leukemia stem cells^11,35. Similarly, the proliferation of P31/FUJ, a human leukemia cell line harboring CALM-AF10 fusion, depended on ENL and DOT1L (Fig. 4b). In this cell line, MORF, but not MOZ, was more critical for proliferation and appeared to be the dominant isozyme. HBO1 is essential for both P31/FUJ and HB1119, a human leukemia cell line harboring MLL-ENL. Taken together, ENL, DOT1L, and MOZ/MORF KATs are essential for CALM-AF10-mediated leukemic transformation.

**Fig. 4: ENL co-factors and MYST family KATs determine survival in leukemia cells.**

Inhibition of MOZ/MORF-mediated acetylation induces dissociation of MOZ/ENL and CALM-AF10 complexes from target chromatin

To further dissect the role of MOZ/MORF-mediated acetylation in ENL-mediated functions, we examined the effects of MOZ/MORF inhibition on CALM-AF10-bearing leukemia cells (i.e., P31/FUJ) using WM1119, a MOZ/MORF KAT inhibitor³⁶. A reduction in bulk acetylation of histone H3K14/23 (H3K14/23ac) was observed in P31/FUJ cells after WM1119 treatment (Fig. 5a). WM1119 completely inhibited the proliferation of P31/FUJ cells, while it slowed down proliferation (but failed to induce complete differentiation) of MLL translocation-induced leukemia cell lines (i.e., HB1119, MV4-11, and MonoMac-6) and Nucleophosmin mutation (NPMc)-bearing leukemia cells (i.e., OCI-AML3) at 10 µM (Fig. 5b and Supplementary Fig. 6a). WM3835, another MYST KAT inhibitor for MOZ/MORF KATs with more profound inhibitory effects on HBO1¹¹, had similar anti-proliferative effects on P31/FUJ cells, but not on HB1119, MV4-11, and OCI-AML3 cells (Supplementary Fig. 6b), despite effective inhibition of histone H3K14 acetylation (Supplementary Fig. 6c). These results indicate that MLL leukemia cells are critically dependent on the presence of MOZ/MORF/HBO1 proteins but not their KAT activity. EPZ-5676, a DOT1L KMT inhibitor, had anti-proliferative effects on both P31/FUJ and MLL translocation-induced leukemia cell lines similar to those reported in previous studies in other disease models (Fig. 5a, b)^37,38. Neither WM1119 nor EPZ-5676 affected the proliferation of K562 cells (Supplementary Fig. 6a). From these results, we conclude that CALM-AF10 leukemia cells are uniquely dependent on the acetylation activity of MOZ/MORF KATs.

**Fig. 5: MOZ/MORF-mediated acetylation is required for the localization of the MOZ/ENL complex and CALM-AF10 at the target chromatin.**

To elucidate the mechanism of action of these inhibitors, we cultured HEK293T cells in the presence of WM1119 for 5 days, which substantially decreased bulk H3K14/23ac (Supplementary Fig. 6d). This was observed as early as 24 h post-treatment (Fig. 5c). The HOXA5 and HOXA9 expression levels were also reduced by WM1119 treatment (Fig. 5d). In addition, ChIP-qPCR analysis showed that the presence of ENL, MOZ, and DOT1L was reduced at the HOXA5 and HOXA9 loci (Fig. 5e), suggesting that MOZ/MORF-mediated acetylation is implicated in the recruitment and retention of MOZ- and DOT1L-complexes to the target chromatin. IP-WB analysis of the chromatin fraction of HEK293T cells that expressed FLAG-tagged ENL showed that WM1119 treatment reduced the amount of ENL in the chromatin fraction but did not attenuate MOZ/ENL complex formation (Fig. 5f). These results suggest that chromatin recruitment or retention of the MOZ/ENL complex is hampered by MOZ/MORF KAT inhibition. Consequently, CALM-AF10 recruitment was reduced by WM1119 treatment (Fig. 5g). Treatment with EPZ-5676 effectively reduced di-methylation of histone H3 lysine 79 (H3K79me2; Supplementary Fig. 6d), lowered HOXA5 and HOXA9 expression in HEK293T cells (Fig. 5d), and reduced the chromatin retention of MOZ and ENL (Fig. 5e). These results suggest that both MOZ/MORF-mediated lysine acetylation and DOT1L-mediated lysine methylation maintain the presence of MOZ- and DOT1L-complexes at the HOXA loci, promoting CALM-AF10-mediated leukemia.

Pharmacological inhibition of the MOZ/MORF KATs suppresses CALM-AF10-mediated leukemia in vivo

We tested the antitumor effects of the MOZ/MORF KAT inhibitor on CALM-AF10 leukemia cells in vivo. First, P31/FUJ cells were transduced with a modified luciferase gene (LUC2Red) and transplanted into immunocompromised mice. After engraftment was confirmed by measuring luciferase-mediated bioluminescence using an in vivo imaging system (IVIS), WM1119 was administered at 50 mg/kg three times a day for 2 weeks (Fig. 6a). The treatment markedly suppressed leukemia cell expansion and prolonged the survival of the recipient mice.

**Fig. 6: Pharmacological inhibition using the MOZ/MORF KAT inhibitor suppresses CALM-AF10-mediated leukemia in vivo.**

We then examined the effects of MOZ/MORF inhibition on murine HPCs immortalized with a variety of AF10 fusions. WM1119 exhibited a substantial anti-proliferative effect on CALM-AF10-, DDX3X-AF10´-, and NUP98-AF10´-ICs ex vivo and induced complete differentiation in most cell lines (Fig. 6b, c). It also induced the differentiation of MOZ-TIF2-ICs, which is dependent on the intrinsic KAT activity of MOZ-TIF2 (Supplementary Fig. 7a)^7,39. In contrast, the treatment only moderately slowed the proliferation of MLL-ENL-ICs (Fig. 6b). MLL-AF10-ICs exhibited a range of anti-proliferative behaviors (Supplementary Fig. 7a), suggesting that the MOZ/MORF KAT inhibitor is generally effective for AF10 translocation-induced leukemia but less effective for MLL translocation-induced leukemia, in which MLL fusion proteins are recruited to the target chromatin via the MLL modules (Figs. 5b and 6b). The IC50 of CALM-AF10-ICs in terms of colony formation was 12 nM, compared to 12 µM in MLL-ENL-ICs (Supplementary Fig. 7b, c). The DOT1L inhibitor suppressed the proliferation of CALM-AF10-ICs ex vivo, with a stronger anti-proliferative effect on CALM-AF10-ICs than MLL-ENL-ICs, consistent with the relatively fast kinetics of the attenuation of proliferation induced by Dot1l knockout in CALM-AF10-ICs (Fig. 4a).

We further examined the antitumor effects of WM1119 on CALM-AF10-mediated leukemia in an immunocompetent context. Primary leukemia cells harvested from moribund mice were transduced with LUC2Red ex vivo and transplanted into secondary syngeneic recipients (Fig. 6d). WM1119 treatment effectively suppressed leukemogenesis in an immunocompetent milieu. These results demonstrate that MOZ/MORF KATs are a unique vulnerability of AF10 translocation-induced leukemia in vivo.

Dual inhibition of MOZ/MORF KATs and DOT1L KMT cooperatively induces differentiation

To elucidate the mechanisms of the antitumor effects of MOZ/MORF and DOT1L inhibition, we identified the genes directly regulated by ENL in P31/FUJ cells. ChIP-seq analysis of P31/FUJ cells using a specific anti-ENL antibody showed that ENL was localized to the MYC, MYB, MEIS1, and HOXA genes (Fig. 7a). A surrogate marker for active transcription, RNAP2 with its CTD phosphorylated at Ser5 on the heptapeptide motif (RNAP2 Ser5-P), was detected at these ENL-target genes. The average distribution of ENL and RNAP2 Ser5-P at the promoter-proximal coding regions was less prominent in P31/FUJ cells compared to that in HEK293T cells probably due to low protein expression of the components of MLL/MOZ/AEP-mediated transcriptional activation system (Supplementary Fig. 8a–c), suggesting that general transcription is relatively low in P31/FUJ cells partly due to the low presence of ENL. The expression of these ENL-target genes was suppressed by the MOZ/MORF KAT and DOT1L KMT inhibitors in a time-dependent manner (Fig. 7b). After the inhibition of MOZ/MORF KATs or DOT1L KMT, ITGAM (the gene coding for CD11b) expression substantially increased, indicating that myeloid differentiation was induced. Owing to the low protein expression of endogenous MOZ/MORF KATs and DOT1L (Supplementary Fig. 8c), ChIP analysis of their genomic localization using available antibodies was technically difficult; therefore, we performed ChIP-qPCR analysis of ENL (a shared component of the MOZ, AEP, and DOT1L complexes), ING4 (a MOZ complex component), Cyclin T1 (an AEP component), and RNAP2 Ser5-P on P31/FUJ cells with WM1119 treatment (Fig. 7c). WM1119 treatment reduced the presence of ENL and its cofactors at these target genes, accompanied by a reduction of the ChIP signal of RNAP2 Ser5-P. This suggests that WM1119 displaces ENL from the target promoters and impairs AEP-mediated transcriptional activation in CALM-AF10 leukemia cells.

**Fig. 7: Inhibition of MOZ/MORF KATs reduces ENL-mediated oncogene activation in CALM-AF10 leukemia cells.**

EPZ-5676 more profoundly downregulated the expression of MEIS1, HOXA5, and HOXA9, compared to that of MYC and MYB (Fig. 7b). Therefore, the dependencies in MOZ/MORF KATs and DOT1L KMT in CALM-AF10-mediated gene activation seemed to slightly differ for each key oncogene.

A greater reduction in oncogene expression and more advanced differentiation were induced at lower concentrations when the two drugs were simultaneously added to the culture (Fig. 8a–c). A similar cooperative effect was seen on another leukemia cell line carrying CALM-AF10 fusion, termed KP-Mo-TS⁴⁰ (Supplementary Fig. 9a). In contrast, the proliferation of normal human CD34 + cells was unaffected under the conditions where that of P31/FUJ cells was severely impaired (Fig. 8d, e), suggesting that the combined inhibition of MOZ/MORF KATs and DOT1L KMT selectively induces differentiation of CALM-AF10 leukemia cells. Next, we examined the effects of the dual inhibition of MOZ/MORF KATs and DOT1L KMT in vivo. Administration of WM1119 (35 mg/kg) and EPZ-5676 (20 mg/kg) three times per day for 2 weeks substantially reduced the leukemia burden compared to the single-drug treatment (Fig. 8f and Supplementary Fig. 9b). Thus, the combination therapy with MOZ/MORF KATs and DOT1L KMT inhibitors could improve therapeutic outcomes in AF10 translocation-induced leukemia.

**Fig. 8: Dual inhibition of MOZ/MORF KATs and DOT1L KMT cooperatively induces differentiation of CALM-AF10 leukemia cells.**

Discussion

In this study, we showed that AF10 fusions exert their leukemic potential via the MOZ-ENL-DOT1L axis. The ENL protein in the AF10 fusion complexes requires an intact YEATS domain that binds to acetylated histone H3 lysine 18/27 (H3K18/27ac)^31,32 and MOZ/MORF KATs⁷, and an intact AHD domain that binds to DOT1L and AF4 family proteins⁸. XPO1 is reportedly associated with the NES in CALM³³ and fuses with AF10 in human leukemia⁴¹. The current paradigm states that XPO1 serves as a recruiting factor that binds to the HOXA loci and recruits AF10 fusion complexes³³. However, our results suggest an alternative mechanism in which ENL binds to the HOXA loci via MOZ/MORF KATs, recruiting AF10 fusion/DOT1L complexes (Fig. 9). We have previously shown that MOZ targets CpG-rich promoters via association with MLL and RNAP2 complexes⁷. Here, we showed that ENL and DOT1L were localized at the HOXA loci in a MOZ-dependent manner in the absence of the CALM-AF10 fusion (Fig. 3e). Thus, the NES-XPO1 interaction is unlikely to be a decisive targeting mechanism but is rather required for the overactivation of HOXA genes. MLL recruits CBP/p300 KATs to provide H3K18/27ac marks on which the AEP complex is formed⁷. In MLL translocation-induced leukemias, constitutive recruitment of AEP to CpG-rich promoters by MLL fusions drives leukemic transformation, as an artificial fusion protein of the targeting module and the AHD domain, which lacks the YEATS domain, was able to transform HPCs (see MTM-AHD in Fig. 1a). In contrast, CALM-AF10 requires an intact YEATS domain of ENL that confers targeting ability to MOZ/MORF complexes, suggesting that emerging YEATS domain inhibitors may be highly effective against AF10 translocation-induced leukemia^42,43,44. Our results support a model where ENL plays a critical role as a targeting factor for MOZ/MORF-occupied chromatin (Fig. 9). A portion of NUP98 proteins has been shown to localize in a nucleoplasmic fraction away from the nuclear pore complex and associates with an active transcriptional factory in eukaryotes^45,46,47, likely as a complex with XPO1 and NES-containing proteins⁴⁸. Thus, the NES-XPO1-NUP98 interaction may play an active role in transcriptional activation by sequestering the HOXA loci in the proximity of the active transcriptional factories.

**Fig. 9: MOZ-dependent recruitment of AF10 fusion complex leads to gene activation.**

We propose that the inhibition of MOZ/MORF KATs can be used as a therapeutic strategy for AF10 translocation-induced leukemia. MOZ/MORF-mediated acetylation activity appears to be uniquely required for AF10-mediated leukemogenesis (Figs. 5, 6). We found that the presence of the MOZ/ENL complex on chromatin was decreased upon MOZ/MORF KAT inhibition (Fig. 5e, g). This decrease of the MOZ/ENL complex induces the dissociation of CALM-AF10 from the target chromatin. Mechanistically, the removal of H3K14/23ac may attenuate the chromatin binding of the MOZ/ENL complex because it contains a reader module for H3K14/23ac⁴⁹ (Fig. 9).

WM1119 has shown negligible adverse side effects in vivo³⁶, and exhibited some antitumor effects toward MLL translocation-induced leukemia ex vivo⁵⁰. In this study, we demonstrated excellent antitumor effects of WM1119 in vivo in murine models of AF10 translocation-induced leukemia. Importantly, WM1119 was much more effective in AF10 translocation-induced leukemia than in MLL translocation-induced leukemia likely due to its direct effects on chromatin targeting by AF10 fusion proteins. ENL-target genes had locus-specific differential dependencies on DOT1L KMT, where DOT1L had a greater influence on MEIS1, HOXA5, and HOXA9 compared to MYC and MYB in P31/FUJ cells (Fig. 7b). Simultaneous inhibition of MOZ/MORF KATs and DOT1L KMT induced marked reductions in the expression of these key oncogenes and exerted an antitumor effect at lower concentrations. Thus, the MOZ/MORF KAT inhibitor and its combination with DOT1L KMT inhibitors may provide novel therapeutic strategies for this malignant subtype of leukemia.

Methods

Vector constructs

For protein expression vectors, cDNAs obtained from Kazusa Genome Technologies Inc⁵¹. or DNA fragments synthesized by DNA synthesis services were cloned into the pMSCV (for retrovirus production), pCDH (for lentivirus production), or pCMV5 (for transient expression) vector using restriction enzyme digestion and DNA ligation. The MSCV-neo MLL-AF10 vectors have been previously described⁸. sgRNA-expression vectors were constructed using the pLKO5.sgRNA.EFS.GFP vector⁵². The target sequences of sgRNA are listed in Supplementary Tables 1, 2.

Cell lines

In the earlier phase of the study, we used HEK293T cells donated by Michael Cleary, which were authenticated by the JCRB Cell Bank in 2019. Later, we used the HEK293T cells purchased from ATCC. HEK293T cells deficient of MOZ and DOT1L were generated by transfection of pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10A)-based gene editing vectors⁵³ carrying two different sgRNAs for each gene and subcloning. Colonies derived from a single-cell clone were expanded and examined for protein expression by WB. The sequences for sgRNA are listed in Supplementary Table 3. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin (PS). The platinum-E (PLAT-E) ecotropic virus-packaging cell line—a gift from Toshio Kitamura⁵⁴—was cultured in DMEM supplemented with 10% FBS, puromycin, blasticidin, and PS. The human leukemia cell lines P31/FUJ (purchased from JCRB), HB1119 (a gift from Michael Cleary)⁵⁵, U937 (purchased from JCRB), MonoMac6 (purchased from DSMZ), and K562 (a gift from Michael Cleary)⁵⁵ were cultured in RPMI 1640 medium supplemented with 10% FBS and PS. KP-Mo-TS cells (a gift from Issay Kitabayashi)⁴⁰ were cultured in RPMI 1640 medium supplemented with 20% FBS and PS. MV4-11 cells (purchased from ATCC) were cultured in Iscove’s Modified Dulbecco’s medium (IMDM) supplemented with 10% FBS and PS. OCI-AML3 cells (purchased from DSMZ) were cultured in α-Minimum Essential Media (MEM) with 20% FBS and PS. Murine myeloid progenitors immortalized by various transgenes were cultured in RPMI 1640 medium supplemented with 10% FBS and PS, containing murine stem cell factors (SCF), interleukin-3 (IL-3), and granulocyte-macrophage colony-stimulating factor (GM-CSF; 1 ng/mL of each). Cells were cultured in an incubator at 37 °C and 5% CO₂ and routinely tested for mycoplasma using a MycoAlert Mycoplasma Detection Kit (Lonza).

Western blotting (WB)

Proteins were separated electrophoretically on an SDS-PAGE gel and transferred onto nitrocellulose sheets using a mini transblot cell (Bio-Rad). The nitrocellulose sheets were blocked with 5% skim milk in PBS-T (phosphate-buffered saline containing 0.1% Tween 20) for 1 h, rinsed twice with PBS-T, and incubated with primary antibodies (listed in Supplementary Table 6) in a 5% skim milk and PBS-T suspension overnight. The blots were then washed twice with PBS-T and incubated with peroxidase-conjugated secondary antibodies (listed in Supplementary Table 6) for 3 h in a suspension of 5% skim milk in PBS-T. Chemiluminescence was performed using an ECL chemiluminescence reagent (GE Healthcare). The antibodies used in this study are listed in Supplementary Table 6. The uncropped scans of the blots are included in the Source Data file.

Virus production

Ecotropic retroviruses were produced using PLAT-E packaging cells (a gift from Toshio Kitamura)⁵⁴. Lentiviruses were produced in HEK293T cells using the pMDLg/pRRE, pRSV-rev, and pMD2.G vectors, all of which were gifts from Didier Trono⁵⁶. Virus-containing media were harvested 24–48 h after transfection and were used for viral transduction.

Myeloid progenitor transformation assay

The myeloid progenitor transformation assay was performed as previously described²⁴. BM cells were harvested from the femurs and tibiae of 5-week-old female C57BL/6 J mice. c-Kit⁺ cells were enriched using magnetic beads conjugated with an anti-c-Kit antibody (Miltenyi Biotec), transduced with a recombinant retrovirus by spinoculation, and plated (4 × 10⁴ cells/sample) in a methylcellulose medium (IMDM, 20% FBS, 1.6% methylcellulose, and 100 µM β-mercaptoethanol) containing murine SCF, IL-3, and GM-CSF (10 ng/mL each). During the first culture passage, G418 (1 mg/mL) was added to the culture medium to select the transduced cells. Hoxa9 expression was quantified using qRT-PCR after the first passage. Cells were then re-plated once every 5 days with a fresh medium. Colony-forming units were quantified per 10⁴ plated cells for each passage.

In vivo leukemogenesis assay

The in vivo leukemogenesis assay was performed as previously described⁵⁷. Cells positive for c-Kit (2 × 10⁵), prepared from mouse femurs and tibiae, were transduced with retroviruses by spinoculation and intravenously transplanted into sublethally irradiated (6 Gy) 7–8-week-old female C57BL/6 JJcl (C57BL/6J) mice. Moribund mice were euthanized, and the cells isolated from the BM were freeze-stocked and later subjected to secondary transplantation. For secondary leukemia, leukemia cells (2 × 10⁵) were transplanted in the same manner as the primary transplantation. The study protocol was approved by the Institutional Animal Care and Use Committee of the National Cancer Center.

RT-qPCR

Total RNA was isolated using an RNeasy Mini Kit (Qiagen) and reverse-transcribed using a Superscript III First Strand cDNA Synthesis System (Thermo Fisher Scientific) with oligo (dT) primers. Gene expression was analyzed by qPCR using TaqMan probes (Thermo Fisher Scientific). Relative expression levels were normalized to those of GAPDH/Gapdh or ACTB and determined using a standard curve and relative quantification method, as per the manufacturer’s instructions (Thermo Fisher Scientific). The commercially available PCR probe sets used in this study are listed in Supplementary Table 6.

Fractionation-assisted chromatin immunoprecipitation (fanChIP)

Chromatin fractions from HEK293T and P31/FUJ cells were prepared using the fanChIP method³⁴. Cells were suspended in CSK buffer [100 mM NaCl, 10 mM PIPES (pH 6.8), 3 mM MgCl₂, 1 mM EGTA, 0.3 M sucrose, 0.5% Triton X-100, 5 mM sodium butyrate, 0.5 mM DTT, and protease inhibitor cocktail] and centrifuged (400 × g for 5 min at 4 °C) to remove the soluble fraction. The pellet was resuspended in MNase buffer [50 mM Tris-HCl (pH 7.5), 4 mM MgCl₂, 1 mM CaCl₂, 0.3 M sucrose, 5 mM sodium butyrate, 0.5 mM DTT, and protease inhibitor cocktail] and treated with MNase at 37 °C for 3–6 min to obtain oligonucleosomes. The MNase reaction was then stopped by adding EDTA (pH 8.0) to a final concentration of 20 mM. Equal amounts of lysis buffer [250 mM NaCl, 20 mM sodium phosphate (pH 7.0), 30 mM sodium pyrophosphate, 5 mM EDTA, 10 mM NaF, 0.1% NP-40, 10% glycerol, 1 mM DTT, and EDTA-free protease inhibitor cocktail] were added to increase solubility. The chromatin fraction was cleared by centrifugation (17,700 × g for 5 min at 4 °C) and subjected to IP with specific antibodies and protein-G magnetic microbeads (Invitrogen) or with anti-FLAG M2 antibody-conjugated beads (Supplementary Table 6). The immunoprecipitates were then washed five times with washing buffer (1:1 mixture of lysis buffer and MNase buffer with 20 mM EDTA) and eluted in elution buffer (1% SDS and 50 mM NaHCO₃). The eluted material was analyzed by WB, qPCR, and deep sequencing.

RNA-Seq

Total RNA was extracted from cells prepared using RNeasy Kit (Qiagen), and its quantity and purity were analyzed using a Bioanalyzer (Agilent Technologies). Deep sequencing was performed using a TruSeq Stranded mRNA Library Prep Kit (Illumina) and HiSeq2500 (Illumina) with 51-bp single-end reads at the core facility of Hiroshima University. Sequenced reads were mapped to the mouse genome assembly mm9 using STAR⁵⁸, and read counts were analyzed using ‘featureCounts’⁵⁹. Differentially expressed genes (DEGs) (False Discovery Rate (FDR) < 0.05) were obtained using TCC R package^60,61. The gene set of DEGs with < 0.01 FDR was analyzed using Metascape⁶² and GSEA⁶³ for pathway enrichment analyses. Hierarchical clustering and principal component analysis were performed using R. DEGs were visualized using the ComplexHeatmap R package⁶⁴.

ChIP-qPCR and ChIP-seq

The material eluted by fanChIP was extracted using phenol/chloroform/isoamyl alcohol. DNA was precipitated with glycogen, dissolved in TE buffer, and analyzed by qPCR (ChIP-qPCR) or deep sequencing (ChIP-seq). The qPCR probe/primer sequences are listed in Supplementary Table 4. For deep sequencing, the DNA was further fragmented (~150 bp) using a Covaris M220 DNA shearing system (M&M Instruments Inc.). Deep sequencing was then performed using a TruSeq ChIP Sample Prep Kit (Illumina) at the core facilities of Hiroshima University and the University of Tokyo. Data were visualized using Integrative Genome Viewer (The Broad Institute). Raw reads in the FASTQ format were trimmed using Cutadapt and aligned to the reference genome hg19 using BWA^65,66. Accession numbers and sample IDs are listed in Supplemental Table 5.

sgRNA competition assay

Cas9 was introduced via lentiviral transduction using a pKLV2-EF1a-Cas9Bsd-W vector⁶⁷. Cas9-expressing stable lines were established using blasticidin (10–30 µg/mL) selection. The sgRNA sequences, listed in Supplemental Tables 1, 2, were either designed using the CCTop design tool⁶⁸ or adopted from previous reports^11,69. The targeted sgRNA was co-expressed with GFP via lentiviral transduction using the pLKO5.sgRNA.EFS.GFP vector⁵². Percentages of GFP⁺ cells were determined by FACS analysis 2 days post-sgRNA transduction and then measured every 4 days.

FACS analysis

One million cells were incubated with PE-conjugated anti-CD11b antibody (Supplementary Table 6) for 1 h on ice, and washed with 1 mL of staining media (PBS containing 3% FBS). Then, the cells were centrifuged, resuspended in fresh staining media, and analyzed with FACS Melody (BD Bioscience). Alive cells were gated as in Supplementary Fig. 10.

Ex vivo culture of human CD34 + cells

Human hematopoietic stem cell—CD34 + cells the from fetal liver (purchased from Cell Applications, INC.) were pre-cultured in Hematopoietic Stem Cell Culture Medium (Cell Applications, INC.) for 4 days and plated in methylcellulose-based medium (MethoCult^TM H4435 Enriched, STEMCELL Technologies) in the presence of designated drugs for 6 days. For comparison, P31/FUJ cells were also plated in the same conditions for 15 days.

Drug administration and monitoring by IVIS

The LUC2 luciferase gene in pGL4.10 (AY737822) was modified by introducing a Ser284Thr mutation⁷⁰. The modified LUC2 gene (LUC2Red) was fused to the P2A self-cleaving peptide sequence and the puromycin resistance gene; then, it was cloned into a pCDH vector (System Biosciences, LLC). Human P31/FUJ leukemia cells and murine CALM-AF10 leukemia cells (CAAF-bm0317) were transduced using lentiviral gene transfer and maintained in puromycin. P31/FUJ-LUC2Red cells were transplanted into sublethally irradiated (2.5 Gy) SCID (C.B-17/Icr-scid/scidJcl) mice (7-week-old females). CAAF-bm0317-LUC2Red cells were transplanted into sublethally irradiated (6 Gy) C57BL/6JJcl mice (7–8-week-old females). Leukemia burden was monitored using an in vivo imaging system (IVIS)(Lumina LT, Perkin Elmer) and D-luciferin (VivoGlo Luciferin, in vivo grade, Promega) as per the manufacturer’s instruction.

Statistics and reproducibility

Statistical analysis was performed using GraphPad Prism 8 and Microsoft Excel software. Data are presented as mean ± standard deviation (SD). Multiple comparisons were performed using one-way or two-way ANOVA; all statistical tests were two-sided. Welch’s T-test was performed on two-group comparisons. Mouse transplantation experiments were analyzed by a log-rank (Mantel-Cox) test. Statistical significance was set at P ≤ 0.05. All the experiments with WB analysis were independently performed at least twice and confirmed their reproducibility.

Study approval

All the animal experimental protocols were approved by the Institutional Animal Care and Use Committee of the National Cancer Center (Tokyo, Japan).

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data supporting the findings of this study are available within the article, in the supplementary information, and in the source data. ChIP-seq and RNA-seq data have been deposited at the DDBJ (DNA Data Bank of Japan) Sequence Read Archive as fastq files [https://ddbj.nig.ac.jp/public/ddbj_database/dra/fastq/] and as WIG files [https://ddbj.nig.ac.jp/public/ddbj_database/gea/experiment/E-GEAD-000/] under the accession numbers and sample IDs listed in Supplementary Table 5. Further information and requests for resources and reagents should be directed to and will be fulfilled by Akihiko Yokoyama (ayokoyam@ncc-tmc.jp). Source data are provided with this paper.

References

Cozzio, A. et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17, 3029–3035 (2003).
Article CAS PubMed PubMed Central Google Scholar
Huntly, B. J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587–596 (2004).
Article CAS PubMed Google Scholar
Meyer, C. et al. The MLL recombinome of acute leukemias in 2017. Leukemia 32, 273–284 (2018).
Article CAS PubMed Google Scholar
Mohan, M. et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 24, 574–589 (2010).
Article CAS PubMed PubMed Central Google Scholar
Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167–178 (2005).
Article CAS PubMed Google Scholar
Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I. & Cleary, M. L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17, 198–212 (2010).
Article CAS PubMed PubMed Central Google Scholar
Miyamoto, R. et al. Activation of CpG-rich promoters mediated by MLL drives MOZ-rearranged Leukemia. Cell Rep. 32, 108200 (2020).
Article CAS PubMed Google Scholar
Okuda, H. et al. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia. J. Clin. Invest. 127, 1918–1931 (2017).
Article PubMed PubMed Central Google Scholar
Doyon, Y. et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 21, 51–64 (2006).
Article CAS PubMed Google Scholar
Takahashi, S. et al. HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis. Elife https://doi.org/10.7554/eLife.65872 (2021).
MacPherson, L. et al. HBO1 is required for the maintenance of leukaemia stem cells. Nature 577, 266–270 (2020).
Article ADS CAS PubMed Google Scholar
Yokoyama, A. Role of the MOZ/MLL-mediated transcriptional activation system for self-renewal in normal hematopoiesis and leukemogenesis. FEBS J. https://doi.org/10.1111/febs.16180 (2021).
Ku, M. et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet. 4, e1000242 (2008).
Article PubMed PubMed Central Google Scholar
Mendenhall, E. M. et al. GC-rich sequence elements recruit PRC2 in mammalian ES cells. PLoS Genet. 6, e1001244 (2010).
Article PubMed PubMed Central Google Scholar
Katsumoto, T. et al. MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev. 20, 1321–1330 (2006).
Article CAS PubMed PubMed Central Google Scholar
Jude, C. D. et al. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell. Stem Cell 1, 324–337 (2007).
Article CAS PubMed PubMed Central Google Scholar
Thomas, T. et al. Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev. 20, 1175–1186 (2006).
Article ADS CAS PubMed PubMed Central Google Scholar
Calvanese, V. et al. MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment. Nature 576, 281–286 (2019).
Article CAS PubMed PubMed Central Google Scholar
Brandimarte, L. et al. DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia. Haematologica 99, 64–66 (2014).
Article PubMed PubMed Central Google Scholar
Bond, J. et al. Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. Blood 124, 3023–3025 (2014).
Article PubMed PubMed Central Google Scholar
Chaplin, T. et al. The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene. Blood 86, 2073–2076 (1995).
Article CAS PubMed Google Scholar
Dreyling, M. H. et al. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc. Natl Acad. Sci. USA 93, 4804–4809 (1996).
Article ADS CAS PubMed PubMed Central Google Scholar
Soler, G. et al. Identification of GSX2 and AF10 as NUP98 partner genes in myeloid malignancies. Blood Cancer J. 3, e124 (2013).
Article CAS PubMed PubMed Central Google Scholar
Okuda, H. & Yokoyama, A. Myeloid progenitor transformation assay. Bio. Protocol. https://doi.org/10.21769/BioProtoc.2626 (2017).
Okuda, H. et al. MLL fusion proteins link transcriptional coactivators to previously active CpG-rich promoters. Nucleic Acids Res. 42, 4241–4256 (2014).
Article CAS PubMed PubMed Central Google Scholar
Deshpande, A. J. et al. The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia 25, 1718–1727 (2011).
Article CAS PubMed Google Scholar
Asnafi, V. et al. CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood 102, 1000–1006 (2003).
Article CAS PubMed Google Scholar
Suzuki, M. et al. Nuclear export signal within CALM is necessary for CALM-AF10-induced leukemia. Cancer Sci. 105, 315–323 (2014).
Article CAS PubMed PubMed Central Google Scholar
Conway, A. E., Scotland, P. B., Lavau, C. P. & Wechsler, D. S. A CALM-derived nuclear export signal is essential for CALM-AF10-mediated leukemogenesis. Blood 121, 4758–4768 (2013).
Article CAS PubMed PubMed Central Google Scholar
Brandimarte, L. et al. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. Blood 121, 5064–5067 (2013).
Article CAS PubMed Google Scholar
Wan, L. et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature 543, 265–269 (2017).
Article ADS CAS PubMed PubMed Central Google Scholar
Erb, M. A. et al. Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543, 270–274 (2017).
Article ADS CAS PubMed PubMed Central Google Scholar
Conway, A. E., Haldeman, J. M., Wechsler, D. S. & Lavau, C. P. A critical role for CRM1 in regulating HOXA gene transcription in CALM-AF10 leukemias. Leukemia 29, 423–432 (2015).
Article CAS PubMed Google Scholar
Miyamoto, R. & Yokoyama, A. Protocol for fractionation-assisted native ChIP (fanChIP) to capture protein-protein/DNA interactions on chromatin. STAR Protoc. 2, 100404 (2021).
Article CAS PubMed PubMed Central Google Scholar
Au, Y. Z. et al. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. Leukemia https://doi.org/10.1038/s41375-020-1001-z (2020).
Baell, J. B. et al. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature 560, 253–257 (2018).
Article ADS CAS PubMed Google Scholar
Chen, L. et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 27, 813–822 (2013).
Article CAS PubMed Google Scholar
Daigle, S. R. et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122, 1017–1025 (2013).
Article CAS PubMed PubMed Central Google Scholar
Shima, H. et al. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion. Int J. Hematol. 99, 21–31 (2014).
Article CAS PubMed Google Scholar
Narita, M. et al. Consistent detection of CALM-AF10 chimaeric transcripts in haematological malignancies with t(10;11)(p13;q14) and identification of novel transcripts. Br. J. Haematol. 105, 928–937 (1999).
Article CAS PubMed Google Scholar
Aumann, W. K. et al. Fusion of the CRM1 nuclear export receptor to AF10 causes leukemia and transcriptional activation of HOXA genes. Leukemia https://doi.org/10.1038/s41375-020-0998-3 (2020).
Garnar-Wortzel, L. et al. Chemical inhibition of ENL/AF9 YEATS domains in acute Leukemia. ACS Cent. Sci. 7, 815–830 (2021).
Article CAS PubMed PubMed Central Google Scholar
Ma, X. R. et al. Discovery of selective small-molecule inhibitors for the ENL YEATS domain. J. Med. Chem. 64, 10997–11013 (2021).
Article CAS PubMed PubMed Central Google Scholar
Christott, T. et al. Discovery of a selective inhibitor for the YEATS domains of ENL/AF9. SLAS Disco. 24, 133–141 (2019).
Article CAS Google Scholar
Kalverda, B., Pickersgill, H., Shloma, V. V. & Fornerod, M. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell 140, 360–371 (2010).
Article CAS PubMed Google Scholar
Xu, H. et al. NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive Leukemogenesis. Cancer Cell 30, 863–878 (2016).
Article CAS PubMed PubMed Central Google Scholar
Terlecki-Zaniewicz, S. et al. Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression. Nat. Struct. Mol. Biol. 28, 190–201 (2021).
Article CAS PubMed PubMed Central Google Scholar
Oka, M. et al. The mobile FG nucleoporin Nup98 is a cofactor for Crm1-dependent protein export. Mol. Biol. Cell 21, 1885–1896 (2010).
Article CAS PubMed PubMed Central Google Scholar
Qiu, Y. et al. Combinatorial readout of unmodified H3R2 and acetylated H3K14 by the tandem PHD finger of MOZ reveals a regulatory mechanism for HOXA9 transcription. Genes Dev. 26, 1376–1391 (2012).
Article CAS PubMed PubMed Central Google Scholar
Yan, F. et al. KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene expression programs. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-20-1459 (2021).
Nagase, T. et al. Exploration of human ORFeome: high-throughput preparation of ORF clones and efficient characterization of their protein products. DNA Res. 15, 137–149 (2008).
Article CAS PubMed PubMed Central Google Scholar
Heckl, D. et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 32, 941–946 (2014).
Article CAS PubMed PubMed Central Google Scholar
Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
Article ADS CAS PubMed PubMed Central Google Scholar
Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063–1066 (2000).
Article CAS PubMed Google Scholar
Tkachuk, D. C., Kohler, S. & Cleary, M. L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 71, 691–700 (1992).
Article CAS PubMed Google Scholar
Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463–8471 (1998).
Article CAS PubMed PubMed Central Google Scholar
Okuda, H. & Yokoyama, A. In vivo Leukemogenesis Model Using Retrovirus Transduction. Bio. Protocol. https://doi.org/10.21769/BioProtoc.2627 (2017).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Article CAS PubMed Google Scholar
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
Article CAS PubMed Google Scholar
Sun, J., Nishiyama, T., Shimizu, K. & Kadota, K. TCC: an R package for comparing tag count data with robust normalization strategies. BMC Bioinforma. 14, 219 (2013).
Article Google Scholar
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
Article CAS PubMed Google Scholar
Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).
Article ADS PubMed PubMed Central Google Scholar
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Article ADS CAS PubMed PubMed Central Google Scholar
Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016).
Article CAS PubMed Google Scholar
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011).
Article Google Scholar
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
Article CAS PubMed PubMed Central Google Scholar
Tzelepis, K. et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid Leukemia. Cell Rep. 17, 1193–1205 (2016).
Article CAS PubMed PubMed Central Google Scholar
Stemmer, M., Thumberger, T., Del Sol Keyer, M., Wittbrodt, J. & Mateo, J. L. CCTop: An intuitive, flexible and reliable CRISPR/Cas9 target prediction tool. PloS One 10, e0124633 (2015).
Article PubMed PubMed Central Google Scholar
Yamauchi, T. et al. Genome-wide CRISPR-Cas9 screen identifies Leukemia-specific dependence on a pre-mRNA metabolic pathway regulated by DCPS. Cancer Cell 33, 386–400 e385 (2018).
Article CAS PubMed PubMed Central Google Scholar
Branchini, B. R., Southworth, T. L., Khattak, N. F., Michelini, E. & Roda, A. Red- and green-emitting firefly luciferase mutants for bioluminescent reporter applications. Anal. Biochem 345, 140–148 (2005).
Article CAS PubMed Google Scholar

Download references

Acknowledgements

We thank Hagumu Sato, Ikuko Yokoyama, Kanae Ito, Megumi Enmi, Makiko Okuda, Yuzo Sato, Megumi Nakamura, Etsuko Kanai, Ayako Yokoyama, Satoshi Takahashi, Ryo Miyamoto, and Hiroshi Okuda for technical assistance. We also thank the members of the Shonai Regional Industry Promotion Center for their administrative support. This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI grants (19H03694 to A.Y.; 22H03109 to A.K., and A.Y.; 22KK0119 to Y.K., A.K., and A.Y.; 17H01567 and 20H05699 to T.M.). This work was also supported in part by research funds from the Yamagata prefectural government and the city of Tsuruoka.

Author information

These authors contributed equally: Yosuke Komata, Akinori Kanai.

Authors and Affiliations

Tsuruoka Metabolomics Laboratory, National Cancer Center, Tsuruoka, Yamagata, 997-0052, Japan
Yosuke Komata & Akihiko Yokoyama
Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, the University of Tokyo, Kashiwa, Chiba, 277-0882, Japan
Akinori Kanai
Department of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Hiroshima, 734-8553, Japan
Akinori Kanai & Toshiya Inaba
Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Fukuoka, 812-8582, Japan
Takahiro Maeda

Authors

Yosuke Komata
View author publications
You can also search for this author in PubMed Google Scholar
Akinori Kanai
View author publications
You can also search for this author in PubMed Google Scholar
Takahiro Maeda
View author publications
You can also search for this author in PubMed Google Scholar
Toshiya Inaba
View author publications
You can also search for this author in PubMed Google Scholar
Akihiko Yokoyama
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

Y.K. and A.Y. conducted the experiments; A.K. and T.I. performed deep sequencing; A.K. analyzed the deep sequencing data; T.M. provided the CRISPR-mediated screening data. A.Y. conceived the project; A.Y. supervised the project; A.Y. wrote the paper.

Corresponding author

Correspondence to Akihiko Yokoyama.

Ethics declarations

Competing interests

A.Y. received a research grant from Sumitomo Pharma Co. Ltd. The remaining authors declare no competing interests.

Peer review

Peer review information

Nature Communications thanks Xiaobing Shi and Florian Grebien for their contribution to the peer review of this work. Peer reviewer reports are available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary info

Peer Review File

Reporting Summary

Source data

Source Data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Komata, Y., Kanai, A., Maeda, T. et al. MOZ/ENL complex is a recruiting factor of leukemic AF10 fusion proteins. Nat Commun 14, 1979 (2023). https://doi.org/10.1038/s41467-023-37712-5

Download citation

Received: 18 May 2022
Accepted: 22 March 2023
Published: 08 April 2023
DOI: https://doi.org/10.1038/s41467-023-37712-5

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.